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Chelation of Cadmium
by Ole Andersen*
The toxicity of cadmium is determined by chelation reactions: in vivo, Cd2+ exists
exclusively in coordination complexes with biological ligands, or with administered
chelating agents.
The Cd2+ ion has some softcharacter, butitis not atypical softion. Ithas a high degree
ofpolarizability, and its complexes with soft ligands have predominantly covalent bond
characteristics. Cd2+ forms the most stable complexes with soft donor atoms (S>>N>O).
The coordination stereochemistry of Cd2+ is unusually varied, including coordination
numbers from 2 to 8. Even though the Cd2+ ion is a dlO ion, disturbed coordination
geometries are often seen. Generally, the stability of complexes increases with the
number of coordination groups contributed by the ligand; consequently, complexes of
Cd2+ withpolydentate ligands containing SH groups are verystable. Cd2+ inmetallothio-
nein (MT) is coordinated with 4thiolate groups, and the logstability constantis estimated
to 25.5.
Complexes between Cd2+ and low molecular weight monodentate orbidentate ligands,
e.g., free amino acids (LMW-Cd), seem to exist very briefly, and Cd2+ is rapidly bound to
high molecular weight proteins, mainly serum albumin. These complexes (HMW-Cd) are
rapidly scavenged from blood, mainly by theliver, and Cd2+ is redistributed to MT. After
about 1 day the Cd-MT complex (MT-Cd) almost exclusively accounts for the total
retained dose ofCd2+, independent ofthe route ofexposure. MT-Cdis slowly transferred
to and accumulated in kidney cortex. The acute toxicity and interorgan distribution of
parenterally administered Cd2+ are strongly influenced by preceding MT induction, or
decreased capacity for MT synthesis; however, the gastrointestinal (GI) uptake of Cd2+
seems unaffected by preceding MT induction resulting in considerable capacity for Cd2+
chelation in intestinal mucosa, and this finding indicates that endogenous MT is not
involved in Cd2+ absorption. The toxicity of parenterally administered Cd2+ is strongly
enhanced when administered as complexes with NTA or STPP, but it is much decreased
when administered as a complex with EDTA. In chronic oral exposure thetoxicity and GI
uptake of Cd2+ is not changed when Cd2+ is administered as a complex with the
detergent formula chelating agents NTA, EDTA and STPP. The uptake of Cd2+ from
ligated intestine in vivo was not affected by administration of Cd2+ as complexes with
CYS or GSH, but significantly reduced by complexation with EDTA or BAL. The acute
toxicity oforally administered Cd2+ is reduced when Cd2+ is administered as a complex
withEDTA. Therenaltoxicity and depositionofCd2+ is markedlyincreased whenCd2+ is
parenterally administered as MT-Cd. Orally administered Cd-MT is taken up by intesti-
nal mucosa and transferred to kidneys, where MTis broken down. Perfusion ofintestinal
loops in situ with MT-Cd induces necrosis ofintestinal mucosa, not observed with Cd2+
alone.
During acute treatment of Cd2+ poisoning the superior agents seem to be the po-
lyamino-polycarboxylates, especially DTPA, which increases renal excretion. The time
lapse between Cd intoxication and antidote administration is critical due to the rapid
intracellular accumulation ofCd2+, mainly in liver. During chronic Cd2+ exposure, BAL
significantly increases biliary excretion of Cd2+, and part of the mobilized Cd2+ is
chelated out ofMT.
Introduction smelter production of Cd has increased from
10,000 short tons in 1958 to 18,780 in 1974. Cd is The element cadmium (Cd) was discovered in mainly obtained as a by-product from smelting
1817. Since then Cd has gained increasing tech- zinc ore, where Cd often is present as an impurity
nological importance, and the annual world (0.2-0.3%). Cd metal and compounds of Cd are
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nuclear fission reactors. Human exposure to Cd
has taken place in industries producing and uti-
lizing Cd, but serious exposures have also oc-
curred in the zinc industry, in operations (mainly
welding) on Cd-plated items, in scrap remelting,
and due to environmental pollution. Ibday Cd is
ubiquitous in the biosphere. Due to the great
concern regarding present and future human
health aspects of Cd pollution, a number of re-
views of chemical, environmental and biological
effects ofCd have appeared (1-8).
Cd is very toxic to mammals both during acute
and chronic exposure. In biological systems, solu-
ble Cd2+ inevitably exists as coordination com-
plexes with biological ligands, and the toxicity of
Cd2+ is beyond doubt mediated through chelation
reactions at the target. Although the exact mech-
anism of Cd toxicity has not been established in
any organism, themodifying effect ofmetallothio-
nein on Cd toxicity is widely recognized (9,10).
Recent reviews of the chemistry of metals with
special emphasis on biological effects have been
prepared by Martell, Schubert and Nieboer (11-
13), and two recent reviews (14,15) were devoted
to the coordination chemistry ofcadmium.
Chemistry of Cd
A chemical description ofthe Cd2+ ion, in rela-
tion to those metal ions known to interplay with
Cd2+ inbiological systems, i.e., Cu2+ and Zn2+, as
well as those donor groups available for complex
formation in the biological systems, may contrib-
ute to the understanding ofthe ligand preference
of Cd2+ during Cd intoxication, as well as the
possibilities for induction of ligand exchange re-
actions during chelation therapy.
Together with Zn and Hg, Cd forms group IIB
in the periodical table ofthe elements. Although
a few compounds ofCd+ exist, Cd is usually found
in valence +2, with outer electron configuration
4d'0. The polarizability of the Cd2+ ion is rather
high (a = 1.8 A3; 16), and coordination bonds
formed with soft donors have a high degree of
covalent character. Organic compounds of Cd
(R2Cd and RCd+, R = aliphatic) exist (diethylcad-
mium is used in the production oftetraethyllead),
but are unstable and decompose upon contact
with water.
The stability of complexes formed between Cd
and polar groups, in proteins (mainly those con-
taining N, 0 or S), nucleic acids (the phosphate
moieties or the bases) or added chelating agents,
depend on energy changes associated with com-
plex formation. The size ofthese energy changes
depend on chemical features of the ligand (and
the metal ion, in this case Cd2+), the most impor-
tant being stereochemical conditions at the lig-
and, "hardness/softness," the chelate effect and
rate effects. These fourfactors ofcourse interplay,
and they cannot be considered independent of
each other.
Stereochemistry ofCd2+ Complexes
Information about the stereochemistry ofcoor-
dination complexes of Cd2+ with biological lig-
ands in aqueous solution is of great importance
for understanding the biological effects of Cd2+.
However, the largest part of information avail-
able concern the coordination chemistry of Cd2+
complexes in the solid state, examined by X-ray
crystallographic methods. An extensive review of
the stereochemistry ofcoordination compounds of
Cd was recently published by Tuck (14). From the
dlO state ofthe Cd2+ ion the coordination chemis-
try ofCd2+ would be expected to be dominated by
examples of coordination to four donors of two
electrons, according to the inert gas rule. Many
examples ofthis are known. However, cadmiumis
also found in a large number of complexes with
other coordination numbers ranging from 2 to 8,
in many cases with the structure distorted from
regular tetrahedral or octahedral. In Table 1 ex-
amples of coordination compounds of Cd2+ are
given. Itshouldbenotedthat, exceptforthe aquo-
cation of Cd2+, the data pertain to nonaqueous
conditions, and use ofthese datafor extrapolation
to biological systems is questionable.
The only known examples of two-coordinate
Cd2+ species occur in gas phase. In aqueous phase
such structures are hydrated. The CdBr3- com-
plex has pyramidal structure in aqueous solution,
indicating hydration. The only known example of
tetrahedral CdO4 coordination is in crystalline
CdZn(PO4)2. CdN4 kernels have not been defina-
tely proven. However, afewexamples ofCdC4are
known, and CdS4 coordination is observed with
several chelating agents withS-donor ligands, all
with more or less distorted Td structure. The
stereochemistry of five-coordinated Cd2+ is var-
ied, and many examples of distorted C4, and D3h
symmetryhave beenreported. Examples ofCdO5,
CdN5 and CdS5 coordination are known, in most
cases forming dimers or polymers.
The aquo-cation ofCd2+ is (Cd(H20)62+. Several
examples of CdO6 and CdN6 kernels have been
reported. The highest number of S reported in
hexacoordinate Cd2+ complexes is 4, in the ker-
nels CdO2S4 and CdN2S4, and Cd2+ complexes
containing S in the kernel with coordination
numbers higher than six have not been reported.
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Table 1. Stereochemistry ofcoordination complexes ofCd2+.
Coordin.
Na Compound Kernel Stereochemistry Reference
2 CdX2(gas phase), X=F,Cl,Br,I D,oh symmetry (17)
3 CdBr3-(non aq. sol.) D3h symmetry (18)
4 CdZn2(PO4)2 CdO4 Distorted Td; polymeric lattice (19)
Cd(CN)2 en'2C6H6 CdC4 Td; polymeric structure (20)
Cd(2-methyl thioxine)2 CdN2S2 Distorted Td; monomer (21)
CdCl2thiourea2 CdCl2S2 Distorted Td; monomer (22)
Cd(Et-xanthate)2 CdS4 Distorted Td; each S from different xanthate (23)
5 Cd2Zn(PO4)2 CdO5 frigonal pyramidal; polymeric lattice (19)
Cd(N,N-diethyldithio carbamic acid)2 CdS5 Distorted C4U; dimer (24)
Cd(thioglycollate)2 CdS40 DistortedD3h; polymeric layer (25)
6 [Cd(OH2)6]2+ (aq.sol.) CdO6 Oh (26)
Cd(acetylacetonate)2 CdO6 Approx. Oh; parallel chain structures (27)
[Cd(imidazole)6]CO35H20 CdN6 Approx. Oh (28)
Cd(NCS)2 CdN2S4 Approx. Oh; three-dimensional polymer, NCS-linked (29)
Cd(HCOO)2(thiourea)2 CdO2S4 Approx. Oh; chain polymer, S-bridged (30)
Cd(L-methionate)2 CdO4N2 Distorted Oh (31)
Cd(D-penicillaminate) H20 CdO3S2N Distorted Oh (32)
7 Cd(CH3COO)2-2H20 CdO7 Square-based trigonal cap (33)
Cd(malonate)2 H20 CdO7 Distorted pentagonal bipyramid (34)
8 Cd(NO3)2-4H20 CdO8 Bidentate NO3 on each side ofsquare planar Cd(OH2)4 (35)
Cd(maleate)-2H20 CdO8 Distorted dodecahedron (36)
aN = coordination number.
The stereochemistry of hexacoordinate Cd2+ is
dominated by distorted or approximately Oh
structure. Examples of heptacoordinate Cd2+
complexes with 4-7 0 in the kernel are known,
mainly with distorted pentagonal bipyramidal
structure. In octacoordinate complexes, Cd2+ has
been found in °8 and N8 kernels, mainly with
distorted dodecahedron structure.
Scales for "Hardness/Softness"
The "hardness/softness" (or class A or B charac-
ter) ofmetal ions, and thus their behavior (= lig-
and preference) in aqueous solution, is deter-
mined by physical and chemical characteristics of
the ion. The same, of course, holds true for the
donor groups. Some discrepancy exists in the
chemical literature about whether to consider
Cd2+ a "soft" ion or an "intermediate" ion. A little
scrutinity on this subject may therefore be rele-
vant.
Several authors have developed formal descrip-
tors for tabulating donors and acceptors in com-
plexation reactions into the three classes, "hard"
or class A, "borderline" or "intermediate," and
"soft" or class B. This classification was originally
suggested by Schwarzenbach (37) and Ahrland et
al. (38) and further elaborated by Pearson (39),
mainly on the basis ofdifferences in the stability
ofmetal halide complexes in water. Thus, a typi-
cal hard metal ion has the donor atom preference
sequence: F-> Cl-> Br-> I-, and a typical soft
metal ion has the opposite preference sequence:
I-> Br-> Cl-> F-. Based on this definition,
Cd2+ is a soft ion.
Several softness descriptors are listed in Table
2, and values for Cd2+ and other divalent ions
tabulated: The ionic index correlates well with
ionic interactions and indicates the propensity of
the ion to form ionic bonds (40,41). The ratio of
the sum of ionization energies of an ion over the
ionic index, i.e., rYJIZ2 was used by Williams as a
measure of softness (41). Williams and Hale (41)
defined the softness parameter Q as
Q = AHion(g)(MFn) - AHion(g)(MIn)
1/2 [(AHion(g)(MFn) + AHion(g)(MIn)]
where AHion(g)(MFn) is the coordinate bond en-
ergy, i.e., the enthalpy change for the reaction
MFn Mn + + nF
in the gas phase, and analogously for iodide.
Pearson and Mawbey (42) defined a related soft-
ness parameter
sp= AHion(g)(MFn) - AHion(g)(MIn)
AHIjon(g)(MFn)
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The softness of metals increases with decreasing
Q and decreasing up.
Klopman (43) defined the softness parameter
UK as the difference (in eV) between the empty
frontier orbital energy and the desolvation en-
ergy of a metal ion. Ahrland (44) defined a soft-
ness parameter,
(7A = (In + /xIn)IZ
i.e., the difference between the total ionization
potential and the dehydration energy (-AHKn)
divided by the ion's charge. The CA increase with
increasing softness.
The covalent index, Xm2r, whereXm is the electro-
negativity of the ions, was used by Nieboer and
Richardson (13) to describe softness. The ration-
ale is that Xm is related to the empty frontier
orbital energy of a metal ion, and this parameter
indicates the ability ofthe ion to accept electrons
and form covalent bonds. Xm2r increases with
increasing softness.
In Table 2, several divalent metal ions are
placed in order of average increasing softness, as
based on the softness parameters. A reasonably
good correlation between the different descriptors
is demonstrated, although many different ther-
modynamic functions and experimental measure-
ments have been used. The selection of exclu-
sively divalent ions of course favors this
agreement.
Generally, hard metal ions form stable com-
plexes with hard donors, while soft metal ions
form stable complexes with soft donors. However,
softness itself favors formation of stable com-
plexes. Thus, in a series ofanalogous coordination
complexes between ions with the same charge
and different ligands with the same number of
donor groups, the stability of the complexes de-
pends mainly on the softness of the ion and the
ligand. This is illustrated in Table 3, which gives
the stability constants ofcomplexes between sev-
eral divalent metal ions and different bidentate
ligands. Table 3 demonstrates the general trend
that the stability constants increase downwards
and towards the right. This may be explained by
increasing softness ofthe metals downwards and
ofthe chelating agents' donor groups towards the
right, i.e., the coordination bonds formed have a
high degree of ionic character in the upper left
part of the table and a high degree of covalent
character in the lowerright part. Table 4 summa-
rizes the most important biological ligands,
grouped according to their metal preference.
Thermodynamics of
Complex Formation
The stability of coordination complexes can
conveniently be described by thermodynamic
functions. When n ligands form a coordination
complex with a metal ion,
M +nA-- MAn
the ligational free energy, AGn, is related to the
stability constant:
On= (MAn)/(M)(A)n
through AGn = -RT In jn. The energy change is
contributed by changes in enthalpy, AHn and
entropy, ASn:
AGn = AHn - TASn
AH mainly describes energy changes due tobond-
ing, while TAS mainly describes energy changes
Thble 2. Values ofsoftness parameters for divalent metal ions.
Hard- Metal a Z2 rI Q OK CA Xm2r
nessa ion r Z2
H Be2+ 0.01 9.09 3.02 0.20 0.172 -3.75 1.2 0.85
H Mg2+ 0.10 4.87 0.21 0.167 -2.42 1.4 1.25
H Ca2+ 1.10 4.04 4.45 0.21 0.180 -2.33 0.9 1.00
I Ni2+ 1.00 7.79 3.30 - 0.126 -0.29 2.0 2.50
I Fe2+ 1.20 5.40 4.45 0.127 -0.69 2.1 2.60
I Co2+ 1.20 5.55 4.48 0.130 1.8 2.65
I Mn2+ 1.25 5.00 4.61 0.124 - 2.0 2.00
I Zn2+ 0.80 5.40 5.06 0.12 0.115 3.1 2.20
S Cu2+ 5.55 5.04 0.104 0.55 3.1 2.95
S Cd2+ 1.80 4.12 6.28 0.09 0.081 2.04 3.5 2.80
S Pb2+ 4.80 3.33 0.14 0.131 4.1 3.40
S Hg2+ 2.90 3.63 8.03 0.07 0.064 4.64 4.64 4.10
Reference (16) b c (41) (45) (45) (45) (13)
aH = hard; I = intermediate; S = soft.
bCalculated from the formal charge and the crystal ionic radius (46).
cCalculated from the ionic index and the total ionization potential (45).
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Table 3. Equilibrium constants for complexes between divalent metals and simple bidentate ligands: M + L - ML.
log 3
Hard- Metal Ethylene- Mercapto- Mercapto-
nessa ion Oxalate Glycine diamine acetate ethylamine
H Be2+ 4.08b
H Mg2+ 2.76b 2.22b 0.37c 2.30b
H Ca2+ 3.00c 1.39d 2.21b
I Ni2+ 5.16d 5.78b 7.35b (6.2)f 10.05e
I Fe2+ 3.05d 4.31d 4.34c
I Co2+ 3.84b 4.64b 5.96c 5.84b 7.68e
I Mn2+ 3.2b 2.80b 2.67b 4.38b
I Zn2+ 3.88b 4.96b 5.7b 7.86b 9.90b
S Cu2+ 4.84b 8.15b 10.54b (16)
S Cd2+ 3.89d 4.22b 5.45b 10.97b
S Pb2+ 4.00b 5.47d 7.OOb (8.5)f 11.lOb
S Hg2+ 9.66b 10.3c 14.3b (24)f -
aH = Hard, I = Intermediate, S = Soft. All values from Martell and Smith (47), except as noted.
b250C, ionic strength 0.1.
c25°C, ionic strength 0.5.
d250C.
e300C, ionic strength, 1.0. Table 4. Biological ligands.
fData ofJacobson and lurner (15).
related tothenumberofindependent species, e.g.,
associated with changes in solvation. During
complex formation with highly charged negative
polydentate ligands such as the polyaminopoly-
carboxylates, the main contribution to the stabil-
ity ofthe complex often is the increase in entropy
due to loss ofsolvation, because ofcharge neutral-
ization (Table 5). In the formation of complexes
with uncharged ligands, e.g., the polyamines, the
stability is generally due to decrease in enthalpy.
The reason enthalpy changes are not totally out-
numbered by entropy changes, e.g., during ligand
selection in mixed chelation, is that the high
dielectric constant of water efficiently screens
electrostatic forces.
Chelating ligands form much more stable com-
plexes than unidentate ligands: In series of ana-
logouscomplexes with equal numbers ofthe same
ligand, the stability generally increases with the
number of rings formed. From the displacement
reaction
MAn + Ln-+ MLn + nA
where In is a polydentate ligand with the same
donor atoms asA, Schwarzenbach (49) definedthe
chelate effect as the logarithm to the equilibrium
constant for the displacement reaction. This en-
tity can be related to the change in free energy.
Assuming (what may not always be true, how-
ever) that the change in enthalpy associated with
complex formation is independent on whetherthe
coordination groups are unidentate or bound to-
gether in a polydentate ligand, the chelate effect
should be due to increased entropy. A significant
enthalpy effect is, however, often observed, since
Ligands preferred
by hard ions
OH-
H20
C032-
S042'-
R-O-SO3-
N03-
HP042-
Mono- and diesters
ofphosphate
R-OH
R-COOH
R-CHO
R-CO-R
R-O-R
Ligands preferred
by intermediate or
soft ions
Cl-
NH3
N2
02
RNH2
R2NH
R3N
R=N-R
RCO-N-R
Ligands preferred
by soft ions
R.SH
R,S-R
R-S-S-R
Table 5. Effect ofring size on the chelate effect in the
displacement reaction.
Cd2+[CH3-N(CH2COO-)2]2 -
Cd2+ [(-OOCCH2)2N-(CH2)n-N(CH2COO-)2]
n log Oia G, kcal/mole H, kcal/mole TIS
2 7.2 -5.3 -1.8 3.5
3 2.4 -1.8 1.8 3.6
4 - 1 0.7 4.4 3.7
5 -1.6 1.2 2.8 1.6
aCalculated from AG,200C, 0.1 (48).
mutual repulsive forcesbetweenthe donor groups
are overcome by introducing them into one mole-
cule. The chelate effect may be counteracted by
adverse energy changes, due to necessary confor-
mational changes during complex formation, es-
pecially when strained rings are formed. This is
shown in Table 5: AH more than counteracts the
entropy contribution to stability as the ring size
increases.
253Table 6. Stability ofcomplexes between Cd2+ and polydental ligands, M + L ML.
Ligand Donor groups log i
Malonic acid 2 2.64a
Citric acid 3 3.75a
Ditartronic acid 4 5.44a
Ethylenediamine (en) 2 5.45a
Diethylenetriamine (dien) 3 8.40b
Tiethylenetetramine (trien) 4 10.63a
lmtraethylenepentamine (tetren) 5 14.00a
N,N,N' N-tetra(2-aminoethyl) ethylenediamine (penten) 6 16.10b
Iminodiacetic acid (IDA) 3 5.71a
Nitrilotriacetic acid (NTA) 4 9.78a
N-(2-Hydroxyethyl) ethylenediamine-N,N' N'-triacetic acid (HEDTA) 5 13.10a
Ethylenediaminetetraacetic acid (EDTA) 6 16.36a
Diethylenetrinitrilopentaacetic acid (DTPA) 8 19.00a
a25OC, 0.1. b200C, 0.1. Data from Martell and Smith (47).
At low concentrations of chelant, the chelate
effect is an important contribution to stability.
Forthe formation ofahexacoordinate Cd complex
with a monodentate ligand Cd + 6A -+ CdA6 the
equilibrium constant is:
1(A6)= (CdA6)/(Cd)(A)6
At a decreasing concentration of ligand, the
amount of complex will decrease with (A)6, i.e.,
extremely fast, and for biological ligands (except
water) (A)6 is a very small number. For the for-
mation ofthe analog complex with a hexadentate
ligand containing 6A groups:
Cd + LA6 -- CdLA6
the equilibrium constant is
(LA6) = (CdLA6)/(Cd)(LA6)
and the amount of complex formed is directly
proportional to the concentration ofthe ligand.
Experimentally, the gain in stability due to
chelate ringformation hasbeen foundtobe inthe
order of102perringformed, i.e., PLA6couldbe 1010
PA6 or larger. The obvious consequence for chela-
tion therapy during acute Cd intoxication is that
at the nontoxic chelant concentrations the effi-
ciency ofchelation therapy can be improved most
effectively by increasing the 1 value. This im-
provement can be obtained by increasing the
number of chelate rings formed. According to
Table 6, the introduction of one extra ring may
increase 1 by a factor up to 104 (note that the
complex MLA, is compared with the complex
MLAn+1, thus only part ofthe increased stability
is due to the chelate effect). The other way would
be to increase the softness ofthe chelant's donor
groups. According to Table 3, a change of "N" to
"S" can increase ,B by approximately 4 orders of
magnitude forcomplexes with softmetals. Table 7
Table 7. Stability ofcomplexes between Cd2+ and
substituted IDA.
Compound: Equilibrium Log i
Aliphatic
CH3-N-(CH2COO)2 ML/M-L 6.75a
ML2/ML2 12.43a
Alcohol
HO-CH2-CH2-N(CH2COO)2 ML/M-L 7.24a
ML2M-L2 12.31a
Ether
CH-O-CH2-CH2-N(CH2COO)2 ML/M*L 7.53b
ML2/M-L2 13.18b
Ketone
CH3-CO-CH2-N(CH2COO)2 ML/M-L 7.37a
ML2/M-L2 12.34a
Carboxyl
OOC-CH2-N-(CH2COO)2 ML/M-L 9.78a
ML2/ML2 14.39a
Amine
H2N-CH2-CH2-N(CH2COO)2 ML/M-L 10.53b
ML2/M*L2 16.59b
Mercapto
HS-CH2-CH2-N(CH2COO)2 ML/M-L 16.72b
ML2/M*L2 22.33b
a250C, 0.1.
b2o0C, 0.1. Data from Martell and Smith (47).
demonstrates that the stability ofanalogous com-
plexes of Cd2+ with different compounds formed
by substitution ofthe methyl group in N-methy-
liminodiacetic acid (MIDA) with donor groups of
increasing softness, increases as expected: The
change of-COOH to -CH2SH yields an increase
in stability of 7 to 8 orders of magnitude. It
therefore seems a logical step to test chelants
with as many SH groups as possible. The highest
number of S atoms which can at the same time
coordinate with Cd2+ seems to be 5. In hexacoor-
dinate complexes, Cd2+ can coordinate with S4N2
and S402 (Table 1).
Effective SH-containing chelants for Cd2+
should have two vicinal SH groups (50). The tox-
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Table 8. Rate constants for ligand exchange reactions.a
Exchange rate constant Formation rate constant
Metal Ionic kM-H20, sec-1 Kf,M-lsec-1
ion index H20-H20 L-H20 NTA3- HEDTA3-
Be2+ 9.09 2.1 x 103 102b
Mg2+ 4.87 5.3 x 105 3x 105b
Ca2+ 4.04 4x 108 6-9x 108c 1-1.7x 107
Ni2+ 7.79 3x 104 1-2x 104b 4.8x 105 1x 106
Fe2+ 5.40 3.2 x 106 1-2 x 106b
Co2+ 5.55 1.1-2.4x 106 2X 105-2x 106b 4X 106
Mn2+ 5.00 3.1 x 107 4x 106-5x 107b 5x 108
Zn2+ 5.40 3 x 107 3 x 107b 2.109-1010 1-2 x 109
Cu2+ 5.55 5x 109 2-5 x 108b 2X 108 8.4X 107
Cd2+ 4.12 3 x 108 2.5 x 108c 109-2 x 1010 2.6-108-6.4 x 109
Pb2+ 3.33 7.5x109c 1.5x 1011 23x 109-6 X 1011
Hg2+ 3.63 2x 109 2x109d
aData from Margerum et al. (52).
bSO42
cCH3COO-.
dCl
icity of propanetrithiol is much larger than that
ofBAL and related compounds, mostlikely due to
adduct formation with proteins (50). Conse-
quently, the toxicity may be reduced by introduc-
ing two pairs of vicinal SH groups, favouring
tedrahedral coordination as in the Cd-MT com-
plex. The efficiency of charged chelants as, e.g.,
the polyaminopolycarboxylic acids against the
acute toxicity ofparenterally administered Cd2+
decreases rapidly concomitantly with cellular up-
take of Cd2+, and not with the kinetics of MT
induction (51). High efficiency of SH-containing
chelants against aged Cd2+ deposits requires li-
pophilicity of the agent (50). Thus, the critical
step in successful chelation ofCd2+, except imme-
diately after administration, seems to be trans-
port over the cell membrane, first ofthe chelant
and subsequently ofthe chelate.
By combining chemical considerations, such as
those reviewed above withbiological experiments
it will hopefully be possible to design new and
more effective chelating agents for Cd2+, in order
to antagonize the acute toxicity ofCd2+ as well as
todetoxify aged Cd2+ deposits inthe liver without
inducing renal damage.
Rate Effects
The formation of coordination complexes in
aqueous solution (in complex biological systems it
could be called "ligand selection") is dependent on
rate constants and equilibrium constants. Table 8
demonstrates a correlation between the aptitude
ofdifferent ions for hydration and the ionic-index,
Z2/r. The rate of exchange of water molecules
from the inner hydration layer is largest for the
less stable hydration complexes, and inspection of
Table 8 demonstrates that also the rate ofsimple
displacement reactions, as expected, is inversely
related to the ionic index. The ligand exchange
rates for cadmium are generally large for water
exchange, simple ligand exchange and complex
formation with polydentate ligands (Table 8).
Thus, equilibrium will be reached rather fast,
and after some time the distribution of Cd2+ be-
tween different ligands will reflect (1) the affinity
of Cd2+ for the ligands as discussed above, i.e.,
mainly softness, and (2) stabilizing effects, i.e.,
mainly the chelate effect. Thus, duringthe initial
phase of Cd2+ distribution in the body, equilib-
rium constants dominate, e.g., during complex
formation with serum albumin in the blood
stream, and subsequent ligand exchange from
serum albumin to metallothionein (MT) in the
liver. Ithasbeen demonstrated, however, thatthe
process ofin vitro chelation ofCd2+ out ofthe Cd-
MT complex with EDTA is determined by the
very slow rate of exchange, and not by the equi-
librium (53). It is therefore ofimportance to con-
sider rate constants for ligand exchange during
the discussion ofredistribution ofCd2+ after Cd2+
has been bound to MT.
Ligand exchanges are multistep reactions, and
different mechanisms exist. The attacking ligand
needs an initial coordination site on the complex.
This can be achieved by solvent displacement or
bydisplacingone ofthe coordination groupsofthe
residential ligand. In the first case, the increased
stability ofthe mixed complex will contribute to
facilitate chelate ringopening. Inthe secondcase,
the ring opening and subsequent displacement
normally occur at amuch slowerrate. Duringthe
next step the attacking ligand must become che-
lated to decrease the rate ofdissociation from the
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mixed complex. Steric hindrance often decreases
the exchange rate during reaction steps where
several bulky groups simultaneously approach
the metal ion. The kinetics of ligand exchange
reactions have been extensively reviewed by
Margerum et al. (52).
Effects of Competing Species on
Chelate Stability
In biological systems, the conditional or effec-
tive stability constants 13' for metal chelates may
be several orders of magnitude lower than indi-
catedbythe standardstability constants, ,B shown
in the tables, since competition by other ligands
decreases the concentration offree metal ion, and
competition by other cations, e.g., the H+ ion and
other metal ions, decreases the concentration of
noncomplexed ligand available for chelation. The
most important interfering ions in biological sys-
tems are normally the OH- and H+ ions (-107 M)
and the Ca2+ ion (-10-3 M). The term a is used
for the ratio of the sum of concentrations of all
species of the ion involved in complex formation
with a competing ligand over the concentration of
the free compound available for chelation, and
analogous for competing ions: aL(L) = I(Lj) and
aM(M) = X(Mi). For formation of the complex
LaMbwith one competing chelant and one compet-
ingionpresent, the conditional stability constant,
1' is:
13 (LaMb)
[2:(Li)] z(j)]b
= (LaMb)
aLa(L)aaMb(M)b
and
' = log - a log aL - b log aM
Calculation of 1' for chelation ofCd2+ with EDTA
at pH = 7.4 with 2.5 mM Ca2+ present as in
human serum (54) requires that four different
equilibriabe considered forthehydrogenated spe-
cies ofEDTA, giving
allH =
(EDTA)+(HEDTA)+(H2EDTA)+(H3EDTA)+(H4EDTA)
(EDTA)
1 + P1(H) + 12(H)2 + 13(H)3 + 14(H)4
where the stability constants for the different
hydrogenated forms ofEDTA are: log 1 = 10.17,
log 12 = 6.11, log 3 = 2.68, log P4 = 2.0 (47), and
log a,H = 2.77. Four different hydroxyl com-
plexes ofCd2+ should be considered, having 01 =
4.1, 02 = 7.7, 03 = 10.3 and P4 = 12.0 (47). The a
value can be calculated analogously to the
a-H-value:
aMOH =
1 + OJ(OH)1 + 132(OH)2 + 33(OH)3 + j34(OH)4
with log aMJOH 0.
Thus, competition by OH- ions does not inter-
fere with chelation reactions involving Cd at
physiological pH.
There is only one EDTA species ofCa2+ compet-
ing for Cd, having 1 = 10.61 (47). We can now
calculate aL/ca = 1 + 01[Ca2+]andby approximat-
ing [Ca2+] - 2.5 x 10-3 we find log aL/ca = 7.01.
For the CdEDTA complex, 13 = 16.36 (47). At
the conditions specified the value of 1' can be
calculatedto 16.36 - 2.77 - 7.01 = 6.58 without
taking into account mutual interactions between
competing species: However, due to mutual in-
teractions between ions the standard stability
constants are not valid, and calculation of a-
values in order to determine conditional stability
constants becomes highly speculative. In serum
also Mg2+ (=0.86 mM) (54), Cu2+ + Cu+ (- 19
gM) (54), and Zn2+ (-46 gM) (54) compete for
Cd2+. These metal ions are partially protein-
bound, and exact knowledge about how available
they are for competition is not present. Further-
more, chelation ofCd2+ with serum albumin dur-
ingthe initial phase after Cd2+ exposure andwith
metallothionein later will reduce the conditional
stability constants for complexes of Cd2+ with
chelating agents even more.
Binding of Cd2+ to
Biological Ligands
In vivo, Cd2+can bind to nucleic acids, or to
proteins (Table 4). Several investigations have
demonstrated that Cd2+is not found associated
with low molecular weight compounds like free
amino acids, etc., to any appreciable extend, ex-
cept maybe during a very brief period immedi-
ately after ingress of Cd2+. Proteins offer much
more favorable binding sites for Cd2+than nucleic
acids due to the soft binding sites formed by
cystein residues.
In nucleic acids, the phosphodiester groups of-
fer negatively charged coordination sites for hard
ions like Mg2+ and Ca2 , leading to bonding with
mainly ioniccharacter, while nitrogen-containing
sites on thebases represent donor sites favored by
Cu2+, Cd2+ and Hg2+. Intermediate ions like
Co2+, Mn2+ and Zn2+ can bind to either the phos-
phates or the bases. The deoxyribose moieties,
however, are not suited for complex formation
with metal ions.
A few investigations have yielded information
about complex formation between Cd2+ and free
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bases, nucleosides, and nucleotides. With cytidine
monophosphate Cd2+forms a complex,
[Cd(5'CMP)(H2O)]n, in which Cd2+is pentacoordi-
nate, binding to phosphate groups from three
different 5'-CMP molecules, a water molecule
and to N-3 of a fourth 5'-CMP molecule (55).
With 5' - AMP and NO -, Cd2+ forms a complex
[5'AMP)Cd(NO3)2*HO]2, + in which two Cd2+
ions are octacoordinated andbindtoN-3 andN-9
from two protonated adenine residues, arranged
point symmetrically. Furthermore, the Cd2+ions
coordinate with the same two water molecules,
and each Cd2+ ion coordinates with two of four
NO3- ions. (15,56).
Lessisknown aboutbindingofCd2+ to DNA. In
intact chromosomes from eukaryotic organisms,
the DNA ispresent as ahighly organized complex
with a large number of different chromosomal
proteins, histones as well as nonhistone proteins,
the latter containing SH groups, which offerbind-
ing sites for Cd2+. A very limited amount of
information is available concerning interaction of
Cd2+ with chromosomal proteins. In vitro expo-
sure ofhuman lymphocytes to Cd2+ can, however,
inactivate the mitotic spindle (57,58), most likely
by binding of Cd2+ to SH groups in spindle pro-
teins. This inhibition of spindle function, which
wasalso observedwith Hg2+, was counteracted by
metallothionein induction afterprolonged in vitro
exposure to Cd2+or Hg 2+ (57,58). Sephadex G-75
chromatography oflysates ofhuman lymphocyte
cultures after 72 hr exposure to '09Cd in vitro
demonstrated binding ofCd to MT (Fig. 1).
The affinity of Cd2+ for proteins parallels to
some degree the size ofthe stability constants for
the complexes between the Cd2+ ion and the
amino acids in the proteins. However, both the
carboxyl groups and the amino groups are modi-
fied by peptide bond formation. Due to the uni-
formity of the peptide bond, functional side
groups in the amino acids become major determi-
nants of the affinity of metal ions for proteins.
Table 9 shows the stability constants for the com-
plexes of several amino acids with Cd2+. Only
histidine and cystein offer good binding sites for
Cd2+ in proteins. Cd2+ can bind strongly to pro-
teins if two SH groups are adjacent, allowing
chelation. In metallothionein, Cd2+ is bound very
strongly (log I = 25.5) (59). Optical studies (60)
and 113Cd-NMR studies (61) have indicated that
in the metallothionein molecule Cd2+ is tetrahe-
drally coordinated to four deprotonated cysteinyl
side groups by thiolate bonds, and that adjacent
Cd2+ ions are linked through single thiolate
bridges.
This strong binding of Cd2+ to MT is in sharp
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FIGURE 1. Sephadex G-75 chromatograms of lymphocyte ly-
sates after in vitro exposure to l09Cd: (A) 5 x 10-5 M Cd2+
4 hr before harvest; (0) 5 x 10-5 M Cd2+ 72 hr before
harvest; (1) elution volume of serum albumin; (2) elution
volumeofmetallothionein; (3) elutionvolumeoflowmolec-
ular weight compounds.
Table 9. Stability ofcomplexes between free amino
acids and Cd2+.a
ML/M-L ML2/M*L2
Amino acid log J log 192
Alanine 3.80b 7.10b
Valine 3.46b 6.46b
Leucine 3.84b 6.54b
Isoleucine 7.00b 8.80b
Proline (8.0)d
Phenylalanine 3.87c 6.73c
¶fryptophane 4.47c 8.18c
Methionine 3.67c 7.03c
Glycine 4.22c 7.69c
Serine (4.84)d (7.4)d
Threonine (4.43)d (7.2)d
Cysteine (9.9)d
Tyrosine 3.57c 6.08c
Asparagine (7.1-8.6)d
Glutamine (7.4)d
Aspartic acid 4.39c 7.55c
Glutamic acid 3.90c (7.9)d
Lysine (5.8)d
Arginine (6.7)d
Histidine 5.39c 9.66c
aValues from Martell and Smith (47), except as noted.
b250C, 0.5.
c250C, 0.1.
dData from Squibb et al. (62).
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contrast with the kinetics of ligand exchange
reactions involving Zn2+. Removal ofZn from MT
by EDTA during pseudo first-order kinetics for
EDTA showed triphasic kinetics with k1 fast, k2
-
10-3 sec-' and K3 = 10-4 sec-1, while the rate
constant for removal ofCd2+ was approximately 3
x 10-6 sec-1 (53), and the rate constant for trans-
fer ofzinc to apo-carbonic anhydrase was found to
be about 103, i.e., about the same rate as the
reaction with free zinc, suggesting that a physio-
logical role for MT could be acting as a zinc donor
to zinc-requiring macromolecules (53). Due to the
high degree of resistance of the Cd-MT complex
against ligand exchange reactions, both favored
by the large stability constant (59) and the slug-
gish reaction ofthe Cd-MT complex with compet-
ing ligands (53), Cd2+ is not likely to be removed
from MT in vivo to any appreciable degree, except
after translocation ofthe Cd-MT complex to the
kidneys, where the MT moiety is broken down,
and Cd2+ is rapidly reassociated with renal MT
(63-65).
The efficiency ofchelating agentsforincreasing
renal excretion ofCd2+ during acute Cd2+ intoxi-
cation is sharply reduced concomitantly with cel-
lular uptake of Cd2+, mainly in the liver (51).
Already 12 hr after administration ofCd2+, only a
limited amount ofthe dose is chelatable by anti-
dotes like DTPA, EDTA and dimercaptosuccinic
acid (66). It is, however, possible to chelate Cd2+
out ofmetallothionein and reduce the whole body
burden as well as the concentration of Cd2+ in
liver and kidneys by daily chelation therapy with
BAL, initiated several days after cessation ofCd
exposure (67). The main excretion route during
BAL-induced mobilization ofaged Cd deposits in
the liver is fecal, due to increased biliary excre-
tion (68).
Effects of Chelation on
Cd2+ Toxicity
The possibilities ofchelating agents for modify-
ing the acute toxicity of Cd2+ depend on the
chelating agent used, the molar ratio between the
chelant and Cd2+, the route of exposure and the
time lapse between exposure to Cd2+ and to the
chelating agent. Reported effects of chelating
agents on acute Cd2+ toxicity include antagonis-
tic effects, no appearant effect, and even enhance-
ment oftoxicity.
Parenteral Exposure
Nitrilotriacetic acid (NTA) increased the acute
toxicity of Cd2+ in rats after subcutaneous expo-
sure (69). Several studies have demonstrated that
subcutaneous exposure of mice to Cd2+ adminis-
tered as a complex with NTA (70) or sodium
tripolyphosphate (STPP) (70,71) increased the
acute toxicity of Cd2+, as indicated by mortality
within 24hr. The reasonforthe enhancedtoxicity
is probably a high hepatotoxicity of these com-
plexes ofCd, since extensive hepatic necrosis was
observed at doses ofCd2+ (3.2 or 3.35 mg/kg body
weight), exerting mild or no hepatotoxicity when
administered alone (70,71). The liver damage in-
duced by the Cd-STPP complex was character-
izedby extensive centrilobularnecrosis seen at 24
hr (71). During a time-course study ofthe induc-
tion of hepatic necrosis after subcutaneous ad-
ministration of the STPP-Cd complex to mice,
Andersen et al. (71) investigated livers of mice
killed 2, 4, 6, 8, 12 and 24 hr after administration
of 30 imole/kg Cd with 90 jimole/kg STPP and
observed pronounced centrilobular blood stasis
and early centrilobular necroses with fragmenta-
tion and lysis of nuclei and swollen hepatocytes
already 6 and 8 hr after administration. This
picture progressed to a more advanced state at 12
hr, and already before 16 hr, 2/10 animals were
dead. At 24 hr, 7/10 animals were dead. In ani-
mals given the same dose of Cd2+ without STPP
the liver histology was normal during the first 12
hr. At 24 hr all animals had survived, and 4/8
animals had normal liver histology, while four
livers showed necrosis ofsingle or several hepato-
cytes with eosionophile, swollen cells and with
admixture of neutrophiles. Focal necroses were
randomly localized. All control animals had nor-
mal livers, and the kidneys of all animals ap-
peared normal. The events inducing liver necro-
sis during Cd-STPP exposure must take place
veryrapidly after administration, since the mini-
mum period required for induction ofhepatic ne-
crosis is 6-8 hr. The enhancement of toxicity
exertedby STPP is mostlikelydue to induction of
increased rate of interorgan distribution of Cd2+
(71): Figure 2 demonstrates that both the trans-
port away fromthe injection site andthe accumu-
lation of Cd2+ in liver and kidneys take place
much faster when Cd2+ is administered as a com-
plex with STPP than when Cd2+ is administered
alone.
Investigation of the binding of Cd2+ to macro-
molecules by Sephadex G-75 chromatography
demonstrated that STPP delayed and decreased
thebindingofCd2+ tometallothionein inthe liver
(Fig. 3). Thus, soon after exposure, when metal-
lothionein induction has not yet taken place, a
high concentration ofCd2+ is present in the liver,
ableto exert afulltoxicpotential. Thedecrease in
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FIGURE 2. Effect of STPP on Cd transport and distribution
among organs: (0) Cd, 30 jmole/kg; (A) Cd, 30 jmole/kg
and STPP, 90 jimole/kg. Each point represents the average
of determinations on four animals. The SEM is shown
when larger than the height ofthe symbol.
the liver content of Cd2+ observed at later times
mostlikely isdue to leakage ofCd2+ from necrotic
liver cells.
Sephadex G-75 chromatography (Fig. 4) of
blood plasma, liver homogenate and kidney ho-
mogenate from animalskilled 20 min after subcu-
taneous (SC) injection of Cd2+ or Cd2+ + STPP
demonstrated that Cd in blood plasma was dis-
tributed in the MW area from serum albumin
down to low molecular weight compounds. In the
100
12
Hours
FIGURE 3. Binding ofCd to proteins: (a) Cd, 30 jmole/kg; (A)
Cd, 30 gmole/kg and STPP, 90 jmole/kg. From elution
profiles like those shown in Fig. 4 the amount of l09Cd
bound to MT was calculated as % oftotal l09Cd eluted from
the column. The values obtained are shown versus time
after injection.
liver, Cd2+ was solely found associated with high
molecular weight proteins (fractions 12-14),
while in kidneys most ofthe Cd2+ was associated
with high molecular weight compounds, but a
small amount eluted in the MT region (fraction
23-25). In liver and kidneys Cd2+ was not found
associatedwith low molecularweight compounds.
There was no difference between the elution pat-
tern between animals injected with Cd and Cd +
STPP. One hour after injection, similar elution
patterns were observed for liver and kidney ho-
mogenates, while all 109Cd in plasma eluted with
high molecular weight compounds, irrespectively
ofwhether Cd or Cd + STPP had been injected.
After Sephadex G-75 chromatography, '09Cd and
109Cd + STPP eluted in the low molecular weight
area (= fraction 40). 109Cd + STPP mixed with
serum albumin eluted in the high molecular
weight area. The unexpected elution pattern of
Cd in plasma observed 20 min after injection has
been verified in several trials. It may be due to
splittingofhigh molecularweight complexes dur-
ing chromatography, leading to extensive trail-
ing.
In a study ofthe effect ofcysteine on the renal
uptake ofCd(72), SC coinjection ofCd2+ and cys-
teine decreased the liver concentration of Cd2+
and increased thekidney concentration ofCd2+ at
0.5-7 hr as well as 24 hr after injection, as com-
pared with the same dose of Cd2+ alone. In con-
trast to the enhancing effect ofNTA and STPP on
acute Cd2+ toxicity, SC exposure ofmice to Cd2+
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FIGURE 4. Distribution ofl09Cd among protein fraction after Sephadex G-75 gel chromatog-
raphy. Same doses as in Figs. 2 and 3.
as a complex with EDTA reduced the acute toxic-
ity, as well as the liver and kidney concentrations
ofCd2+ after 21 days, both when the CdEDTA and
when the Cd2EDTA complex was dominating, as
compared with the same dose of Cd2+ adminis-
tered alone (73). Suzuki and Yamamura (74) in-
jected rats intraperitoneally with Cd2 , uncom-
plexed or complexed with chelating agents with
different affinity for Cd2+, and found after 4 days
that the higher the stability constant ofthe com-
plex with Cd2+, the larger the ratio between the
kidney and liver concentrations of Cd2+, thus
suggesting that the stability constant ofthe com-
plex would determine the interorgan distribu-
tion.
Gastrointestinal Exposure
Eighteen months ofchronic exposure ofmice to
Cd2+ (50 ppm in drinking water) administered as
a complex with NTA (500 ppm), STPP (500 ppm)
or EDTA (50 ppm) did not change the toxicity of
Cd2+, measured as mortality and pathological
proteinuria, and only slight changes in the con-
centrations of Cd2+ in liver and kidneys were
found, as compared with administration of Cd2+
alone (70). Chelation ofCd2+ with EDTA or BAL
reducedthe absorption ofCd2+ from ligated intes-
tine after injection into duodenum in rats, as
measured by 109Cd uptake into intestinal tissue.
In addition, the liver and blood concentrations of
Cd2+ were decreased. BAL reduced the amount of
Cd2+ in the kidneys, while EDTA increased the
amount ofCd2+ in kidneys, yielding a maximum
ataround 1.5 hr, while othermuchweakerchelat-
ing agents (cystein and gluthation) only margin-
ally changed Cd2+ absorption (75).
The mortality in mice during 21 days, after
administration ofCd2+, eitherby stomach tube or
by direct injection into the duodenum was signifi-
cantly decreased when Cd2+ was given as the
CdEDTA complex (Cd:EDTA = 1:4, molar ratio).
However, when the predominating complex was
Cd2EDTA (Cd:EDTA = 1:0.4, molar ratio), the
toxicity was identical to that exertedby the same
dose of Cd2+ administered alone (73). The re-
duced toxicity of the CdEDTA complex was ac-
companied by a reduced liver and kidney burden
of Cd. The reason the toxicity of the Cd2EDTA
complex approaches that of the Cd2+ ion is most
likely that the Cd2EDTA complex can split offone
Cd2+ ion (73). The mortality during 3 weeks after
a single dose of 60 mg/kg Cd2+ given by stomach
tube was not changed when Cd2+ was adminis-
tered as a complex with NTA (600 mg/kg) but was
totally abolished when Cd2+ was complexed with
STPP (600 mg/kg) (76).
Translocation of Cd2+ from
Liver to Kidneys
In experimental animals, the liver has been
found to contain the largest amount ofCd2+ dur-
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ing chronic Cd2+ exposure although the kidneys
after prolonged exposure eventually may contain
the largest concentration of Cd2+ (77,78). The
Cd2+ deposit in kidneys is stable and urinary
Cd2+ excretion is low before tubular damage has
been induced (79,80). Thus, Cd2+ concentrations
ofthe order of200-300 mg/kg in kidneys may be
reached, and such concentrations have been sug-
gested as the critical concentration for induction
of kidney dysfunction (6,81-84). After induction
of tubular damage, urinary Cd2+ rises sharply
(85), and Cd2+ bound to MT is excreted into the
urine (86,87). During the period before induction
oftubular damage the interorgan distribution of
Cd2+ is mainly due to slow translocation of Cd-
MT (and the small amount of non-MT bound
Cd2+) from the liver to the kidneys (78). The
retention half-life ofa single dose ofCd2+ in rats
has been measured to be 73 days in the liver and
at least 1240 days inthe kidneys (88). Most likely
this translocation involves transport ofliver Cd-
MTcomplex, because circulating Cd-MT complex
has been demonstrated in the plasma ofmice and
rats after prolonged Cd2+ exposure (86,87,89-94),
and MT has been demonstrated in the plasma of
rats already 1 day after a single dose ofCd2+, by
the use ofa radioimmunoassay (95). MT has also
been demonstrated in plasma and urine of Cd
exposed humans (94,96-100).
Parenterally administered Cd-MT complex is
preferentially absorbed by renal tubules (101-
104) and exert a much higher renal toxicity than
Cd2+ administered alone (79,103,105-107). After
glomerular filtration and tubular resorption, the
Cd-MT complex is rapidly degraded, and Cd2+ is
re-incorporated into renal MT (63-65,108). Dur-
ing the period of slow translocation ofCd2+ from
liver to kidneys, biliary excretion seems to con-
tribute considerably to Cd2+ detoxification (109).
Nordberg et al. (110) concluded that, after long-
term Cd2+ exposure, the largest amount of solu-
ble Cd2+ in mouse blood cell hemolysate was Cd-
MT complex in erythrocytes. In vitro exposure of
human lymphocytes to 109Cd2+ showed that in-
duction of MT synthesis and Cd-MT complex
formation occur in lymphocyte cytoplasm
(57,111). Quantitation ofCd2+ in plasma as well
as inredandwhite bloodcells, 60hrafterasingle
dose of Cd2+ to rats, showed that, although the
highest concentration ofCd2+ was found in white
blood cells, the most important contribution to
the blood content of Cd2+ was Cd2+ in erythro-
cytes, mainly bound to cell membranes. Cd+ in
the erythrocyte cytosol was partly bound to high
molecular weight proteins, partly to a protein
with MW like MT (112).
Table 10. Effect ofdietary PCB exposure on Cd
transition from liver to kidneys.
l09Cd, % ofinitial dose -
Expt. PCP in diet, Group SD (p)a
No. ppm Liver Kidneys
lb 0 1 50.27 ± 1.72 8.7 ± 1.10
(n=4)
10 2 47.42 ± 3.84 10.80 ± 0.92
(n=5) (ns) (p<0.005)
25 3 50.14 ± 3.59 9.15 ± 0.65
(n=6) (ns) (ns)
50 4 49.18 ± 0.93 11.30 ± 1.77
(n=8) (ns) (p=0.01)
100 5 48 ± 2.33 11.31 ± 1.49
(n =5) (p<0.025) (p<0.0025)
200 6 46.36 ± 2.36 11.66 ± 1.21
(n =8) (p<0.01) (p<0.0025)
2c 0 7 17.74 ± 4.03 29.76 ± 4.0
(n=6)
10 8 15.43 ± 2.72 26.61 ± 3.63
(n=5) (ns) (ns)
25 9 14.25 ± 4.53 27.28 ± 1.22
(n=5) (ns) (ns)
50 10 10.53 ± 2.65 26.82 ± 5.25
(n=5) (p<0.0025) (ns)
100 11 11.42 ± 4.52 30.54 ± 3.84
(n=7) (p<0.05) (ns)
200 12 9.02 ± 2.46 32.48 ± 3.49
(n=5) (p<0.0005) (ns)
aStudent's t-test, two-sided.
blO9Cd dose, SC; 10jmole/kg; 10jCi/animal; animals killed
after 15 days.
C109Cd dose, SC; 0.1 imole/kg; 1 jCi/animal; animals killed
after 15 days.
Effect of Hepatic Damage
on Cd2+ Metabolism
Due to the large deposit ofCd2+ present in the
liver during Cd2+ exposure, it is likely that he-
patic disorders may alter the tissue distribution
ofCd2+. This has been verified in a few investiga-
tions where acute liver damage resulted in rapid
and substantial translocation of aged Cd2+ de-
posits from liver to kidneys. Induction ofhepatic
necrosis by aflatoxin B1 lead to translocation of
Cd2+ administered 1 month earlier from liver to
kidneys. Approximately 40% of the decreased
liver burden of Cd2+ was recovered as increased
kidney burden, most likely transferred as the
MT-Cd complex (113). Intragastric administra-
tion of1 mL/kg CCl4 to rats at least 2 weeks after
the end ofexposure to 200 pm Cd2+ in the drink-
ing water for 1 or 4 months also induced a de-
crease in the liver content of Cd2+, paralleled
with recovery ofsome ofthe Cd2+ in the kidneys.
In this study a strongly increased urinary excre-
tion of Cd2+ as well as proteinuria was also in-
261O. ANDERSEN
duced by CCl4 (114). The proteinuria was largest
in the group ofrats exposed to Cd2+ for 4 months.
In a similar study, aged Cd2+ deposits in the
liver ofrats were also mobilized by hepatic necro-
sis induced by 2.5 mL/kg ofCC14 administered 1
day after cessation of 1-8 weeks exposure to re-
peated SC injections ofCd2+ . The hepatic concen-
tration ofCd2+ was almost reduced by 50% 24 hr
after CCl4 exposure. Highly increased plasma and
urinary concentrations of Cd2+ were found, and
Sephadex G-75 chromatography indicated that
the Cd-MT complex accounted for most of the
Cd2+ present in plasma and urine. The kidney
concentration ofCd2+ was also increased. Only a
small part of the mobilized liver Cd2+ content
was, however, recovered in kidneys. The Cd2+
content in other organs (spleen, small intestine,
pancreas) and in feces was not increased, com-
pared with control animals (115,116). Since CCl4
isnephrotoxic andinducesproximaltubular dam-
age (117), evaluation ofthese studies in relation
to the toxicity of Cd-MT to the proximal renal
tubule is difficult.
Little is known about effects of chronic liver
damage on Cd2+ translocation. In an unpublished
study, Andersen et al. (118) found that the rate of
translocation of Cd2+ from liver to kidneys was
increased in mice with hepatic necrosis induced
by chronic PCB exposure. Mice fed diets contain-
ing 0, 10, 25, 50, 100 or 200 ppm PCB were given
a single SC dose of 109Cd (see Table 10). Dietary
PCB exposure for 36 weeks induced dose-depen-
dent pathological changes. In the group fed 200
ppm PCB centrilobular liver cell enlargement
with increased diameter of both cytoplasm and
nuclei was seen, as well as focal necrosis with
Kupffer cell proliferation. Some confluent ne-
croses, a few macroscopically visible, were also
observed. In mice killed 2 weeks after a single SC
dose of 109Cd2+, slightly lower amounts of Cd2+
were present in the liver and slightly larger
amounts were found in kidneys in animals ex-
posed to 100 and 200 ppm PCB, as compared to
control animals. Fifteen weeks after SC 109Cd2+
exposure, a dose-dependent, highly significant re-
duction in hepatic Cd2+ content was observed;
this decrease was, however, not followed by a
comparable increase in the kidney content of
Cd2+ (Table 10). Thus, during the presumably
very slightly increased rate of translocation of
Cd2+ due to PCB-induced chronic liver damage,
some of the mobilized Cd2+ seem to be excreted,
probably in the urine. Whole body counting ofthe
animals could not demonstrate PCB-induced
changes in the rate of excretion of SC dose of
109Cd2+ during 15 weeks. Thedifference in liver +
kidney burden ofCd2+ between the control group
and the group exposed to 200 ppm PCB at 15
weeks is, however, only about 6% of the initial
dose (Table 10), therebyexplainingwhy apossible
slight increase in detoxification rate was not ob-
served.
So far the effect of acute or chronic liver dam-
age on the renal toxicity ofchronic low level Cd2+
exposure is virtually unknown. The studies re-
viewed here indicate that hepatic Cd2+ mobilized
due to acute or chronic liver damage is not quan-
titatively recovered in the kidneys. The possibil-
ity does, however, exist that humans with liver
damage, e.g., due to excessive alcohol consump-
tion have an increased risk for tubular kidney
damage ifthey are exposedto Cd2+. Furthermore,
people with a high liver burden of Cd2+ due to
former or present Cd2+ exposure may be at risk
for kidney damage if acute liver damage occurs,
e.g., due to hepatitis. Further experimental in-
vestigation ofthis aspect ofCd2+ toxicodynamics
is needed.
Chelation Therapy
Accordingto recent reviews (51,119,120) only a
limitedknowledge is presently available concern-
ing the possibility for chelate treatment of Cd2+
intoxication in humans. Although BAL and
EDTA increase the renal excretion of Cd2+ in
experimental animals, both antidotes have been
reported also to increase the renal injury pro-
ducedby Cd2+ (121,122). Intravenous administra-
tion of CaNa2-EDTA (which is superior to the
sodium salt ofEDTA, which may induce hypocal-
cemic tetany as a complicating side effect) in-
creases the renal excretion of zinc considerably,
and the excretion of iron and copper slightly
(119). Extensive destruction ofproximal tubular
epithelium has been observed in the kidneys of
humans and experimental animals after EDTA
treatment (123-125). Due to the mobilizing effect
on aged Cd2+ deposits, chelation therapy ofacute
Cd2+ intoxication is contraindicated in humans
with any significant previous Cd2+ exposure
(6,119).
In order to maximize the efficiency ofchelation
therapy against atoxic metal ion andto minimize
the unwanted excretion of essential metal ions
(i.e., to obtain a high value of 1B', the conditional
stability constant for the complex between the
toxic ion and the selected chelating antidote),
knowledge aboutthe stabilities ofcomplexes with
competingmetal ionsisnecessary. InTable 11 the
stability constants for complexes between the
most frequently used antidotes and competing
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Table 11. Stabilities ofcomplexes between important chelating agents and Cd2+ or other biologically important ions:
M + L -ML.a
log 1
Compound Ca2+ Mg2 + Cu2 + Zn2 + Cd2+
Sodium tripolyphosphate (STPP) 5.20 5.76 8.3 7.5 6.58
2,3-Dimercaptopropanol (BAL) - 13.5
Penicillamine (PEN)b - 19.5 9.40 10.8
Nitrilotriacetic acid (NTA) 6.39 5.47 12.94 10.66 9.78
Ethylenediaminetetraacetic acid (EDTA) 10.61 8.83 18.70 16.44 16.36
Diethylenetrinitrilotetraacetic acid (DTPA) 10.57 9.34 21.38 18.29 19.0
Ethylene bis(oxyethylenenitrilo)tetraacetic acid (EGTA) 10.86 5.28 17.57 12.6 16.5
aData from Martell and Smith, 25°C, 0.1, except as noted.
b20°C, 0.1.
metal ions are listed. DTPA, which has proven
superior as an antagonist toward the acute toxic-
ity ofCd2+ (126,127), forms a complex with Cd2+
several orders of magnitude more stable than
EDTA, while STPP and NTA, which in fact in-
crease the acute toxicity ofparenterally adminis-
tered Cd2+ (69-71) and also PEN, which is with-
out beneficial effects on acute Cd2+ toxicity
(126,127), form much weaker complexes with
Cd2+.
As indicated above, mobilization of aged Cd2+
deposits in the liver by chelating agents may
increase the risk for development oftubular dam-
age. Cherian and co-workers (50,68) and Von
Burg and Smith (128) have demonstrated that
renal excretion of Cd2+ can be circumvented by
the use of BAL or structurally related di- and
trimercaptans, which increase the biliary excre-
tion of Cd2+. The requirement for induction of
efficient detoxification of the Cd-MT complex in
liver seems to be a relatively lipophilic chelating
agent withtwo adjacent SH groups. Itispresently
not known whether these interesting results per-
tain to the human situation, since the high toxic-
ity of this kind of compound in laboratory ani-
mals seems to contraindicate extensive human
use.
Most published experiments evaluating antag-
onizing effects of chelating agents on acute Cd2+
toxicity have been performed by administration
ofCd2+ to experimental animals by the intraven-
ous or other parenteral routes. Accidental acute
Cd2+ intoxication in humans is, however, always
due to either gastrointestinal or pulmonary expo-
sure. Effects of chelating agents on acute Cd2+
toxicity after administration via these routes are
very poorly investigated, and a very limited
knowledge is available.
Future experiments investigating effects of
chelating agents on acute Cd2+ toxicity, biliary
and urinary excretion and organ distribution of
Cd2+ after administration via these routes are of
great importance for developing chelation ther-
apy regimens applicable to treatment of acute
human Cd2+ poisoning.
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